Key points are not available for this paper at this time.
Background: Phosphoinositide 3 kinase belongs to the enzyme family which is responsible for the development of cellular trafficking and uncontrolled cellular division which in turn to cancer metastasis. Activation of the PI3k-Akt-mTOR pathway tends to promote oncogenesis in Lung Cancer and its mutation leads to resistance in EGFR tyrosine kinase inhibitors. Objective: Inhibition of the initial PI3k receptor through natural bioactive phytocompounds from Argemone mexicana that may prevent the side effects caused by the synthetic medication and improve the patient's life quality as natural medicine. Method: According to the previous research we did the Bioactive phytochemical screening from the methanol extract (AME) and powder (AMP) of A. mexicana leaf by analysing the GC-MS (Agilent), UPLC-QTOF-ESI-MS (Waters India Pvt Limited). Analyzed phytochemicals from the studies were subjected to molecular docking analysis using SeeSAR 9.2 software against PI3K (PDP ID: 4FA6) receptor. Result: GC-MS revealed 40 compounds including Cryptopine (17.5), beta-sitosterol (9.57), and Protopine (8.6) were found as major compounds. LC-MS analysis showed the presence of major compounds with 13 elements compared to the literature survey in both positive and negative ESI ranges. 29 compounds from the GC-MS and LC-MS were selected for analyzing the interaction between the cancer receptor-ligand complex according to the binding strategy. Conclusion: Phytoconstituents such as Galactitol, Succinic acid and N-feruloyltryamine from A. mexicana showed good binding affinity range and maximised hydrogen bonding that may assure possessing anticancer effect by controlling the PI3K pathway. This study would lead a major role in the preliminary screening of Drug Targets against the PI3K receptor.
Manoharan et al. (Tue,) studied this question.